MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,030.00
+30.00 (0.75%)
May 21, 2026, 11:49 AM KST
Market Cap137.10B +20.7%
Revenue (ttm)3.90B
Net Income-12.81B
EPS-373.76
Shares Out34.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume65,618
Average Volume201,102
Open4,020.00
Previous Close4,000.00
Day's Range4,020.00 - 4,315.00
52-Week Range3,325.00 - 8,650.00
Betan/a
RSI23.99
Earnings DateApr 3, 2026

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements